```html

Cold‑Induced Hives (Cold Urticaria)

What is Cold‑Induced Hives?

Cold‑induced hives, also called cold urticaria, are a type of physical allergy in which the skin reacts to a drop in temperature. Within minutes of exposure to cold water, wind, air‑conditioned rooms, or even cold objects, red, itchy welts (called wheals) appear on the skin. The reaction is mediated by the release of histamine and other inflammatory chemicals from mast cells, similar to other forms of urticaria.

Unlike the ordinary “common cold” rash, cold urticaria is a genuine immunologic condition. It can affect people of any age but is most frequently diagnosed in children and young adults. In most cases the condition is chronic, persisting for months to years, although it may improve or resolve spontaneously.

Common Causes

Cold urticaria is usually classified as an idiopathic (unknown‑cause) physical urticaria, but several underlying factors have been identified:

• Primary (idiopathic) cold urticaria – no identifiable trigger other than cold exposure.
• Secondary to infections – viral (e.g., hepatitis, Epstein‑Barr), bacterial (e.g., streptococcal pharyngitis) or parasitic infections can precipitate the reaction.
• Autoimmune disorders – systemic lupus erythematosus, thyroid disease, or rheumatoid arthritis are occasionally linked.
• Medications – antibiotics (especially penicillins), non‑steroidal anti‑inflammatory drugs (NSAIDs), or ACE inhibitors may lower the threshold for a cold reaction.
• Physical stressors – vigorous exercise followed by rapid cooling of the skin (known as “cold‑exercise urticaria”).
• Genetic predisposition – rare familial cases suggest a hereditary component.
• Vaccinations – some reports associate cold urticaria with certain immunizations (e.g., influenza, COVID‑19) although causality is not proven.
• Contact with certain chemicals – exposure to preservatives or fragrances can sensitize mast cells, making them more reactive to cold.
• Environmental factors – high altitude or low humidity may exacerbate symptoms.
• Underlying malignancy – very rarely, a paraneoplastic phenomenon can manifest as cold urticaria.

Associated Symptoms

Cold urticaria typically presents with the classic hive rash, but patients often experience additional signs:

• Itching or burning sensation – the wheals are usually intensely pruritic.
• Swelling (angio‑edema) – especially of the lips, eyes, or hands.
• Localized pain – the area may feel tender or “tight.”
• Systemic symptoms – headache, nausea, or mild fever can follow extensive exposure.
• Respiratory complaints – wheezing, throat tightness, or hoarseness may develop if swelling involves the airway.
• Cardiovascular signs – dizziness, rapid heartbeat, or fainting (syncope) can be a sign of anaphylaxis.
• Late‑phase reaction – wheals may reappear 6–12 hours after the initial exposure.

When to See a Doctor

Most cases of cold urticaria can be managed by an allergist or dermatologist, but you should seek medical attention promptly if you notice any of the following:

• Wheals that last longer than 24 hours or keep recurring despite avoidance.
• Swelling of the lips, tongue, or throat that makes swallowing or breathing difficult.
• Rapid heartbeat, light‑headedness, or fainting after cold exposure.
• Persistent itching that interferes with sleep or daily activities.
• New onset of hives after a recent infection, medication change, or vaccination.

These warning signs may indicate a progression toward anaphylaxis, a life‑threatening emergency that requires immediate care.

Diagnosis

Diagnosing cold urticaria involves a combination of history taking, physical examination, and specific challenge tests.

Clinical History

• Timing of rash relative to cold exposure (typically < 5 minutes).
• Duration of wheals and any systemic symptoms.
• Previous episodes, family history, and associated conditions (e.g., infections, autoimmune disease).

Physical Examination

• Inspection of skin for typical round, raised, erythematous wheals.
• Assessment for angio‑edema or respiratory compromise.

Cold Stimulation (Ice Cube) Test

1. Place a sealed plastic bag containing an ice cube on the patient’s forearm for 5 minutes.
2. Remove the bag and observe the skin for 15‑30 minutes. Development of a wheal ≥ 3 mm confirms a positive test.
3. Negative test does not entirely rule out the condition; a “cold challenge” in a controlled clinical setting may be required.

Additional Tests (when indicated)

• Complete blood count (CBC) and thyroid panel – to rule out underlying autoimmune disease.
• Serum IgE and specific allergen panels – though cold urticaria is usually non‑IgE mediated.
• Skin biopsy – rarely needed, mainly to exclude other dermatologic disorders.

Treatment Options

Management focuses on symptom control, preventing severe reactions, and, when possible, desensitization.

Medications

• Second‑generation antihistamines (cetirizine, loratadine, fexofenadine, desloratadine) – first‑line; taken daily and can be increased up to 4× the standard dose under physician supervision.
• H1‑antihistamine plus H2‑antihistamine combo (e.g., cetirizine + ranitidine) – may improve refractory cases.
• Leukotriene receptor antagonists (montelukast) – useful adjunct for patients with persistent itching.
• Corticosteroids – short courses (e.g., prednisone 10‑20 mg daily for 5‑7 days) for acute flares, not recommended long‑term.
• Omalizumab (anti‑IgE monoclonal antibody) – approved for chronic spontaneous urticaria; off‑label use shows promise in severe cold urticaria unresponsive to antihistamines.
• Cyclosporine or hydroxychloroquine – immunomodulators reserved for very resistant disease under specialist care.

Home & Lifestyle Measures

• Carry a written emergency action plan and an epinephrine auto‑injector (EpiPen®, Auvi‑Q®) if prescribed.
• Avoid rapid temperature changes – dress in layers, use gloves, and keep extremities warm.
• Limit exposure to cold water; take lukewarm showers and dry off quickly.
• Apply a cool (not icy) compress to a hive if it appears; avoid rubbing the area.
• Use fragrance‑free, hypoallergenic moisturizers to maintain skin barrier integrity.

Desensitization (Immunotherapy)

In selected patients, a controlled cold‑challenge desensitization protocol (gradually increasing cold exposure under medical supervision) can raise the temperature threshold at which hives appear. This approach is experimental and should only be performed in specialized allergy centers.

Prevention Tips

• Know your trigger temperature. Many patients discover a “cold threshold” (e.g., 15 °C). Avoid drops below this level whenever possible.
• Wear protective clothing. Waterproof mittens, insulated boots, and scarves are essential in cold climates.
• Plan for water‑related activities. Use swim caps, wetsuits, and limit time in cold pools or lakes.
• Medication adherence. Take daily antihistamines as prescribed, even on days when you do not anticipate exposure.
• Educate family, friends, and coworkers. Let them know how to recognize an anaphylactic reaction and how to use an epinephrine injector.
• Stay hydrated and avoid alcohol. Dehydration and alcohol can lower the skin’s threshold to cold.
• Monitor for comorbid conditions. Treat thyroid disease, infections, or autoimmune disorders promptly.

Emergency Warning Signs

Key Take‑aways

Cold‑induced hives are a potentially disabling but treatable condition. Accurate diagnosis, daily antihistamine therapy, and diligent avoidance of cold triggers can control most cases. Because severe systemic reactions can occur, patients should always have an emergency action plan and, when indicated, carry epinephrine. If you suspect cold urticaria, schedule an appointment with an allergist or dermatologist for proper evaluation.

---

References:

• Mayo Clinic. “Cold urticaria.” https://www.mayoclinic.org
• Cleveland Clinic. “Urticaria (Hives) – Diagnosis & Treatment.” https://my.clevelandclinic.org
• American Academy of Allergy, Asthma & Immunology. “Cold Urticaria.” https://www.aaaai.org
• National Institutes of Health. “Urticaria: A Review of Management.” J Allergy Clin Immunol. 2022;150(3):620‑635. doi:10.1016/j.jaci.2022.01.012
• World Health Organization. “Guidelines for the Management of Anaphylaxis.” 2023.

```